Hide metadata

dc.date.accessioned2022-01-21T18:30:04Z
dc.date.available2022-01-21T18:30:04Z
dc.date.created2021-06-09T21:43:21Z
dc.date.issued2021
dc.identifier.citationLirhus, Sandre Svatun Høivik, Marte Lie Moum, Bjørn Anisdahl, Karoline Melberg, Hans Olav . Incidence and prevalence of inflammatory bowel disease in norway and the impact of different case definitions: A nationwide registry study. Clinical Epidemiology. 2021, 13, 287-294
dc.identifier.urihttp://hdl.handle.net/10852/89961
dc.description.abstractBackground: Countries have different diagnostic procedures and treatment regimens for inflammatory bowel disease (IBD) patients. In addition to differences in population characteristics, completeness of data and health registries, different follow-up time and case definitions can have a large impact on estimates of the incidence and prevalence of IBD. Aim: The aim of this study was to use hospital and prescription data to estimate incidence and prevalence of Crohn’s disease (CD) and ulcerative colitis (UC), using different case definitions. Methods: This study used nationwide data from the Norwegian Patient Registry (2008 to 2017) and the Norwegian Prescription Database (2004 to April 2018). Incidence and prevalence were estimated using different case definitions of an IBD patient, varying the number of IBD-related hospital visits and IBD prescriptions required. The base case definition included patients with at least one IBD hospital visit and two IBD prescriptions or two IBD hospital visits. Results: From 2010 to 2017, 16,758 incident IBD patients fulfilled our base case definition, with 6045 diagnosed with CD (36.1%) and 10,713 (63.9%) with UC. For CD, 47.2% of the patients were male while 53.8% of UC patients were male. The base case incidence varied between 14.1 and 16.0 per 100,000 person-years for CD and 24.7 and 28.4/100,000 person-years for UC patients in the years 2010– 2017. When we required at least two IBD hospital visits, not utilizing the prescription data, the CD incidence was 22.3 per 100,000 person-years in 2010 and 13.9 per 100,000 person-years in 2017. For UC, the incidence was 47.4 and 20.6 per 100,000 person-years in 2010 and 2017. In 2017, the prevalence of CD was 0.27% (95% CI: 0.26– 0.27) and 0.50% (95% CI: 0.490– 0.502) for UC. Conclusion: According to our base case definition, the incidence of IBD in Norway was stable from 2010 to 2017. Both the incidence and prevalence of IBD in Norway is among the highest in the world. Moreover, the study also highlights the consequences of different case definitions.
dc.languageEN
dc.publisherDove Medical Press Ltd.
dc.rightsAttribution-NonCommercial 3.0 Unported
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/
dc.titleIncidence and prevalence of inflammatory bowel disease in norway and the impact of different case definitions: A nationwide registry study
dc.typeJournal article
dc.creator.authorLirhus, Sandre Svatun
dc.creator.authorHøivik, Marte Lie
dc.creator.authorMoum, Bjørn
dc.creator.authorAnisdahl, Karoline
dc.creator.authorMelberg, Hans Olav
cristin.unitcode185,52,11,0
cristin.unitnameAvdeling for helseledelse og helseøkonomi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1914942
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical Epidemiology&rft.volume=13&rft.spage=287&rft.date=2021
dc.identifier.jtitleClinical Epidemiology
dc.identifier.volumeVolume 13
dc.identifier.startpage287
dc.identifier.endpage294
dc.identifier.doihttps://doi.org/10.2147/CLEP.S303797
dc.identifier.urnURN:NBN:no-92558
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1179-1349
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/89961/1/Lirhus%2Bet%2Bal.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial 3.0 Unported
This item's license is: Attribution-NonCommercial 3.0 Unported